UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.                        | FILING DATE           | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-----------------------|----------------------|---------------------|------------------|
| 10/773,480                             | 02/06/2004            | Michel Dib           | FRAV2003/0003 US NP | 7069             |
| 5487<br>ANDREA Q. R                    | 7590 10/27/200<br>YAN | 8                    | EXAM                | IINER            |
| SANOFI-AVENTIS U.S. LLC                |                       |                      | KIM, JENNIFER M     |                  |
| 1041 ROUTE 202-206<br>MAIL CODE: D303A |                       |                      | ART UNIT            | PAPER NUMBER     |
| BRIDGEWATI                             | OGEWATER, NJ 08807    |                      | 1617                |                  |
|  |                       |                      |                     |                  |
|  |                       |                      | NOTIFICATION DATE   | DELIVERY MODE    |
|  |                       |                      | 10/27/2008          | ELECTRONIC       |

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com andrea.ryan@sanofi-aventis.com

|  | Application No.   | Applicant(s)   |   |
|--|---|--|---|
| Interview Summary  | 10/773,480  | DIB ET AL.   |   |
| merview Summary  | Examiner  | Art Unit   |   |
|  | JENNIFER M. KIM   | 1617   |   |
| All participants (applicant, applicant's representative, PTO   | personnel):   |  |   |
| (1) <u>JENNIFER M. KIM</u> .   | (3)   |  |   |
| (2) <u>Mr. Bell</u> .  | (4)   |  |   |
| Date of Interview: 20 October 2008.  |   |  |   |
| Type: a)⊠ Telephonic b)⊡ Video Conference c)⊡ Personal [copy given to: 1)⊡ applicant 2   | r)∏ applicant's representative  | ·]   |   |
| Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:  | e)⊠ No.   |  |   |
| Claim(s) discussed: <u>Pending Claims</u> .  |   |  |   |
| Identification of prior art discussed: <u>none</u> .   |   |  |   |
| Agreement with respect to the claims f)☐ was reached. g  | )⊠ was not reached. h)□ N   | I/A.   |   |
| Substance of Interview including description of the general reached, or any other comments: Mr. Bell discussed that the to both the 5HT1a and the 5HT2c receptors and a low affine cyamemazine, which was not only unexpected but also high (A fuller description, if necessary, and a copy of the amendallowable, if available, must be attached. Also, where no callowable is available, a summary thereof must be attached. THE FORMAL WRITTEN REPLY TO THE LAST OFFICE A INTERVIEW. (See MPEP Section 713.04). If a reply to the GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW DATE, OR THE SUBSTANCE OF THE INTERVIEW CONTROL OF THE SUBSTANCE OF THE INTERVIEW CONTROL OF THE SUBSTANCE OF THE INTERVIEW CONTROL | e compound of the instant invity for the M2 and M3 receptor hely unpredictable.  ments which the examiner agony of the amendments that well.)  CTION MUST INCLUDE THE last Office action has already OF ONE MONTH OR THIRTY | reed would render the substance of the s | etter affinity  er the claims claims  OF THE LICANT IS THIS LATER, TO |
| /JENNIFER M KIM/<br>Primary Examiner, Art Unit 1617  |   |  |   |